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Abstract
Genetic variation underlying hypothalamic pituitary adrenal (HPA) axis over-activity in healthy 
controls and patients with severe forms of major depression has not been well explored but could 
explain risk for cortisol dysregulation.
95 participants were studied: 40 patients with psychotic major depression (PMD); 26 patients with 
nonpsychotic major depression (NPMD); and 29 healthy controls (HC). Collection of genetic 
material was added one third of the way into a larger study on cortisol, cognition, and psychosis in 
major depression. Subjects were assessed using the Brief Psychiatric Rating Scale, the Hamilton 
Depression Rating Scale and the Structured Clinical Interview for Diagnostic and Statistical 
Manual of Mental Disorders. Blood was collected hourly for determination of cortisol from 6pm 
to 9am and for the assessment of alleles for 6 genes involved in HPA Axis regulation.
Two of the 6 genes contributed significantly to cortisol levels, psychosis measures or depression 
severity. After accounting for age, depression, and psychosis, and medication status, only allelic 
variation for the glucocorticoid receptor gene (GR) accounted for significant variance for mean 
cortisol levels from 6pm to 1am (r2=.317) and from 1am to 9am (r2=.194). Interestingly, neither 
depression severity nor psychosis predicted cortisol variance. In addition, GR and corticotropin-
releasing hormone receptor 1 (CRH-R1) contributed significantly to psychosis measures and 
CRH-R1 contributed significantly to depression severity rating.
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Introduction
The stress responsive hypothalamic pituitary adrenal (HPA) axis has been implicated in the 
pathophysiology of mood, anxiety, cognitive, and other disorders. The Axis consists of 
stimulating forward and feedback inhibition loops involving the brain, pituitary, and adrenal 
glands to produce glucocorticoid end products. Several reports have found that particularly 
patients with major depression with psychotic features (PMD) demonstrate elevated activity 
of the HPA axis as compared with nonpsychotic depressives (NPMD) or healthy controls 
(HC) (1-10). PMD patients have been reported to demonstrate significantly elevated 24-hour 
urinary free cortisol levels (1), plasma adrenocorticotropin hormone (ACTH) levels (11), 
afternoon (1-4 pm) cortisol levels (4), nocturnal serum cortisol levels (6), blunted response 
to a mineralocorticoid agonist (7), as well as high rates of non-suppression on challenge with 
dexamethasone and very high post-dexamethasone plasma levels (2, 3, 5, 8, 10). Higher 
cortisol levels have been associated with impaired cognitive functioning in healthy controls 
and depressed patients (12, 13).
The HPA axis, which plays an important role in how humans adapt to environmental 
stressors, consists of the paraventricular nucleus (PVN) of the hypothalamus, the anterior 
pituitary and the adrenal cortex, and is regulated in part through a finely balanced feedback 
system, the disruption of which may contribute to depression. The axis can be activated by 
various neuronal signaling molecules, including serotonin, noradrenaline and neuropeptide 
Y, depending on the type of stress stimulus (14). Once released the corticotropin-releasing 
hormone (CRH) stimulates its receptors CRHR1 and CRHR2, which act synergistically to 
modify the extent and duration of the stress response (15), with arginine vasopressin (AVP) 
and the urocortins providing additional regulation. The eventual result is the synthesis and 
release of the glutocorticord cortisol. Cortisol can act through both the mineralocorticoid 
receptors (NR3C2) and glucocorticoid receptors (NR3C1) and imbalances between these 
two receptors has been implicated in a maladaptive stress response and depression (16). The 
glucocorticoid receptor (NR3C1) is widely expressed throughout the body and brain and is 
involved in a number of physiological processes, many of them linked to the stress response, 
these include metabolic functions, cellular differentiation, and the nervous and immune 
system (17), with NR3C2 acting as a counterbalance in a similar to fashion as CRHR2 to 
promote recovery and a return to homeostasis (16).
Genes for the various hormone components and their receptors have been identified. CRH 
binds to CRH-R2 with less intensity than it does to CRH-R1. In contrast, urocortin 
stimulates CRH-R1 and CRH-R2 at equal potency. Urocortin also binds to urocortion 1-3 
receptors. CRH-R2 distribution in primate brain overlaps with typical stress circuits (18) and 
may play a role in HPA stress responses in man. The currently prevailing theory is that 
CRHR1 and CRHR2 work synergistically, with CRHR2 coming more into play in the 
recovery phase (14). This theory has evolved from the notion that it was involved primarily 
in feeding behaviors (18). Individually AVP only has a weak ability to stimulate the release 
of adrenocorticotropic hormone (ACTH) but working synergistically with CRH, it can 
enhance ACTH release from the pituitary corticotrophes, via AVPR1b and CRHR1 
respectively.
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Genetic variation at the corticotrophin releasing hormone (CRH) locus, in the genes 
encoding its binding protein and type 1 and 2 receptors have been associated with increased 
risk for developing panic disorder (19), post-traumatic stress disorder and major depression 
(20) particularly in the face of early abuse (21-23) as well as response to antidepressants in 
several trials (24). Haplotypes for the glucocorticoid receptors (GR) pointed to a relationship 
with risk for more aggressive disease progression in multiple sclerosis suggestive of 
decreased GR sensitivity (25). However, an earlier paper on GR variation had failed to find 
an association with GR insensitivity (26). Recent studies on specific single nucleotide 
polymorphisms for GR indicate they are associated with altered GR sensitivity (27) and 
increased risk for impaired working memory in healthy controls (28); as well as increased 
risk for attention deficit disorder (29), and depression (30, 31). For the FKBP5 co-chaperone 
for the glucocorticoid receptor (GR), genetic variants appear to confer risk for rapidly 
occurring and treatment responsive episodes of depression with altered responses to CRH/
dexamethasone challenge (DST) in depression (32), as well as for developing major 
depression and post-traumatic stress disorder (33, 34) and dexamethasone non-suppression 
(35).
Variation in HPA axis genes has not been explored in PMD even though the disorder has 
been reported to have the most marked HPA axis abnormality. Herein, we report on genetic 
variants for components of the HPA axis and their relationship to depression, psychosis and 
evening/nocturnal cortisol levels in patients with PMD, NPMD, and healthy controls. The 
specific aims of this project were to determine: 1) do HPA axis genes predict cortisol levels; 
2) do HPA axis genes predict depression or psychosis severity.
Methods
Participants
Psychiatric participants were recruited through inpatient and outpatients facilities at Stanford 
University or self-referred from online and print study advertisements. Forty-nine patients 
with psychotic major depression (PMD) and 52 patients with nonpsychotic major depression 
(NPMD) participated in two waves of a larger study on HPA axis in depression (HPA-2 and 
HPA-3). Part way through the first wave of study, collection of blood samples for genetic 
analysis began. The majority of available subjects consented to provide blood for genetic 
analyses.
Psychotic and nonpsychotic depressed patients were required to have a minimum score of 21 
on the Hamilton Depression Rating Scale (HDRS;(36)) and a minimum score of 6 on the 
Thase Core Endogenomorphic Scale (37), with one exception of a PMD who scored 5. 
These latter two criteria were designed to ensure inclusion of participants with similar 
minimum levels of severity of endogenous-type symptoms. PMDs were also required to 
have a minimum of 5 on the positive symptom subscale of the Brief Psychotic Rating Scale 
(BPRS; (38), which consists of four items: conceptual disorganization, suspiciousness, 
hallucinations, and unusual thought content. A score of 4 on the PSS indicates no positive 
symptoms. NPMD subjects had no history of psychotic symptoms. All patients met the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for a current major 
depressive episode, with or without psychotic features.
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Healthy comparison subjects were recruited through online and print study advertisements. 
Overall 56 healthy controls participated in the larger HPA study and 29 provided blood 
samples. Healthy controls (HC) were assessed for Axis I disorders with theStructured 
Clinical Interview for DSM-IV (SCID; (39). They were required to have a score less than 6 
on the HDRS and have no psychotic symptoms as measured by the BPRS positive symptom 
subscale. Furthermore, they had no current or history of Axis I psychiatric illness. 
Participants were allowed to continue their psychiatric medications but were required to 
maintain a stable medication regimen for at least 1 week prior to the start of the study. 
Depressed patients were taking a combination of antidepressants, antipsychotics, 
anxiolytics, and mood stabilizers.
Exclusion criteria for all groups included major medical illnesses, history of seizures or 
major head trauma, abnormal clinical laboratory tests, pregnant or lactating females, and 
under the age of 18. Participants were excluded for unstable or untreated hypertension, 
cardiovascular disease, or endocrine disorders. Subjects on steroids (i.e. prednisone or 
steroidal inhalers) were not included. Additionally, patients who were actively suicidal, met 
criteria for primary Obsessive-Compulsive Disorder or Post-traumatic Stress Disorder, or 
had a history of substance abuse or electroconvulsive therapy in the previous six months 
were excluded from the study.
A number of subjects recruited were not included in the present analyses because of 
medications that interfere with cortisol levels. As oral contraceptives and hormone 
replacement treatments dramatically increase cortisol, all subjects on these medications were 
removed from the cortisol analyses, as well as several subjects who had missing or 
incomplete cortisol data. In toto, 27 cases were excluded from the study. Thus, 40 patients 
with psychotic depression, 26 patients with nonpsychotic depression, and 29 healthy 
controls participated in this genetics study.
Procedure
The study was approved by the Stanford University Institutional Review Board, and all 
subjects gave written informed consent before screening. Eligibility screening procedures 
included the SCID, HAM-D, BPRS, clinical laboratory tests, comprehensive metabolic 
panel, urine drug screening, and urine screening for pregnancy in female subjects. If 
participants met inclusion criteria at the eligibility screening, they were returned for baseline 
procedures.
At baseline, participants were re-administered the HAMD (36) and the BPRS (38). Subjects 
participated in blood sampling overnight on the Stanford Hospital GCRC. An intravenous 
line was inserted at 4PM and blood collected hourly for cortisol from 6pm to 9am the next 
day. Cortisol data on a subset (40 subjects) were previously reported (6) and included 19 
PMDs, 10 NPMDs, and 11 HCs.
Cortisol Determination
The blood samples were kept frozen at −80 degrees until analysis. Cortisol assays were 
conducted by the Brigham Women’s Hospital, General Clinical Research Laboratory in 
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Boston. The analytic sensitivity for cortisol was 0.4 micrograms/dl with a coefficient of 
variation of less than 7.9%.
Because of the natural diurnal rhythm of the cortisol slopes, the 15-hour blood collection 
period was divided into two phases based on the apparent nadir: the evening level from 1800 
to 0100 hours and the morning level from 0100 to 0900 hours. These epochs correspond to 
the natural descending and ascending slopes of the cortisol rhythm and are based on the 
nadirs observed in previous studies (6) as well as in this sample. Mean time of nadir across 
the groups was 12:32 am (SD=2.26). Figure 1a shows the curve of the cortisol values of the 
overall group from 6 pm until 9 am.
Genetics
Blood was collected for assessment of genetic markers at the following HPA axis loci: CRH, 
CRH-R1, CRH-R2, NR3C1 (glucocorticoid receptor, GR), NR3C2 (mineralocorticoid 
receptor, MR), and FKBP5. Genetic markers were selected using a standard protocol (40) 
that utilizes these criteria: 1) The marker has demonstrated (based on literature) or predicted 
(based on bioinformatic analysis) effects on protein abundance or function; 2) The marker 
has been associated with depression, psychosis, memory performance or the HPA axis 
regulation; 3) The marker is located in a region of interest: exons, 3′UTR, intron boundaries 
(41), or one of the many regulatory elements involved in gene expression; 4) The marker is a 
good predictor (“tagging SNP”) for the other polymorphisms in the gene due to high linkage 
disequilibrium (LD); 5) The tagging marker complements other selected markers to provide 
good LD coverage of the gene.
LD bins and the selection of tagging single-nucleotide polymorphisms (SNPs) were 
predicted using Haploview and the unrelated individuals from the HapMap CEU (N = 60 
individuals of European descent collected in UTAH) (42), which was the closest match to 
our study sample. De Bakker (43) showed that ‘tagging’ SNPs selected using the CEPH 
cohort retained a reasonable level of effectiveness across multiple non-African populations. 
However, in some cases, HapMap either does not contain a particular gene or genomic 
region, or a particular marker of interest was not present within the HapMap CEU cohort. In 
these cases, we utilized other SNP databases such as dbSNP, UCSC, Illumina, Seattle SNPs 
and SNPper. In general only SNPs with a minor allele frequency of 5% or greater were 
considered.
DNA was extracted from EDTA-treated whole blood using the Gentra Puregene kit (Qiagen, 
Valencia, CA). Genotyping was performed using Taqman real-time PCR (Applied 
Biosystems, Foster City, CA). All genotypes were tested for deviation from Hardy Weinberg 
equilibrium.
Tables 1 and 2 summarize the SNPs and their frequencies that were assayed for each HPA 
axis gene. 70 SNPs were assessed, distributed in the following manner: CRH (6 SNPs), 
CRHR1 (21 SNPs), CRH-R2 (18 SNPs), NR3C2 (MR; 15 SNPs), NR3C1 (GR; 10 SNPs), 
and FKBP5 (2 SNPs). SNPs that had no or minimal variability in our sample were excluded 
from the analysis. If SNPs had fewer than 5 subjects across all 3 groups homozygous for the 
rare allele, they were collapsed into the heterozygous group.
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Data Analyses
We used a gene-centric testing strategy in lieu of a SNP-specific approach. Gene-wide tests 
have several advantages (44, 45). When the primary scientific interest is in the gene as a 
whole and its impact on a particular pathway, inconsistencies among individual SNP results 
can be difficult to interpret. In addition, performing a single global test of a gene first 
eliminates the need for a multiple testing penalty, which would impose a more stringent 
significance threshold and reduce power. Individual SNPs can still be evaluated individually 
once the gene as a whole has been found to have a significant association. A number of 
novel, gene-centric testing strategies have recently been proposed (46, 47). However, given 
the small sample sizes, we opted to use a simple strategy employing traditional, well-
established statistical F-tests of multiple predictors for multiple linear regression models.
All analyses were conducted using SPSS statistical software. First, differences in cortisol 
among the groups were examined with ANOVA. Next, the relationship between HPA axis 
variation and individual genes was examined controlling for the well-known effects of age 
on serum cortisol levels. In addition, because this sample consists of both patients with 
depression and healthy comparison subjects, severity of depression and psychosis were also 
accounted for prior to examining the gene contribution. For each of the six genes, we 
conducted multiple regressions for cortisol levels with the following predictors: age, 
psychosis and depression severity, use of psychiatric medications, and all available SNPs for 
that gene. This model was compared to several more parsimonious models: one with age, 
psychosis and depression severity, and medication status; one model with age, psychosis and 
depression severity and another with age only. There is a wide variety of psychiatric 
medications that patients were taking and the sample is not large enough to break them 
down into specific medication classes. Thus, if patients were taking daily antidepressants, 
antipsychotics, anxiolytics, or mood stabilizers, they were deemed positive for the daily 
psychiatric medication variable. A single gene-centric test for each gene was performed 
evaluating the contribution of all SNPs simultaneously, using a standard F-tests for multiple 
predictors to compare it to the model with age, psychosis and depression severity. If the 
gene-centric tests reached significance for an association of overall genetic variation with 
cortisol response, individual SNPs within the gene were subsequently evaluated based on 
coefficients and p-values for that SNP in the presence of age, depression severity, psychosis, 
and all other SNPs.
We performed linear regression analyses to assess the contributions of each gene to 
depression and psychosis severity individually. Depression severity was the total score of 
the 21-item HAMD and psychosis severity was the total score on the Positive Symptom 
Subscale of the BPRS. There was a strong correlation between depression and psychosis 
severity in our sample (r=.555, p<.001). Thus the variance associated with the other clinical 
symptom (depression or psychosis) was accounted for in the first step. Then, all SNPs for a 
specific gene were again entered as independent predictors and a gene-wide test was 
performed based on the significance of the entire model. Again, individual SNP 
contributions were evaluated based on the same multi-SNP model only if the overall gene 
test reached significance. The reported effect of each SNP was adjusted for all other SNPs in 
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the gene. We performed similar analyses for psychosis, with depression severity variance 
removed first, using multiple linear regression.
We then examined the relative contributions of haplotypes for NR3C1 using SNPs first 
reported by Koper et al. (26). Based on these SNPs, we tested 6 haplotypes, previously 
identified by van Winsen et al. (25) For each reported haplotypes, individuals were coded as 
carriers if they carried at least one copy of every allele in the haplotype and as non-carriers if 
they carried no copies for one or more alleles in the haplotype. Each haplotype was then 
tested separately for association with cortisol, depression and psychosis. The cortisol 
regression included age at the first step, depression and anxiety at step 2, and the given 
haplotype. Additional linkage disequilibrium (LD) analysis was carried out using Haploview 
v4.2 (Broad Institute, Cambridge, MA).
Results
Demographic characteristics are summarized in Table 3. The three groups were well 
matched on age and gender. Patients with PMD had significantly higher total HDRS scores 
than did the NPMD’s or HC’s. Differences between the patients primarily reflected 
psychosis-related symptoms in the PMD group. Mean scores on the Thase 
Endogenomorphic Subscale were also significantly higher in the PMD patients, although, 
the differences between clinical groups were relatively small. On the BPRS, PSS scores 
were understandably higher in the PMD group than in the other two groups.
Mean evening cortisol from 6 pm to 1 am was significantly different between the 3 clinical 
groups, F(2,92)=4.19, p=.018, with PMD higher than the other two groups, who did not 
differ from one another (see Figure 1a). Mean 1 am – 9 am cortisol was not different 
between the groups (F(2,92)=.800, ns). These cortisol findings are consistent with our 
previous findings (6).
Only one of the 6 genes—NR3C1 (GR) -- significantly predicted evening cortisol from 
6pm-1am. By itself, age accounted for 5.1% of the variance (F(1,91)=4.93, p=.029. Together 
depression and psychosis accounted for an additional 5.2% of the variance but did not reach 
significance (change r2 = F(2,89)=2.58, p=.082). Daily psychiatric medication use accounted 
for an additional 5.3% of the variance (change r2 = F(1,88)=5.48, p=.022). Genetic variation 
in NR3C1 considering all SNPs simultaneously accounted for an additional 28.8% of the 
variance (change r2 = F(10,78) =4.04 p<.001). Five of the 9 SNPs in this gene attained 
individual statistical significance in this model (rs33888, p=.002; rs2918419 p=001; 
rs10052957, p<.001; rs10482633, p=.002; and rs41423247, p=.009). The overall model with 
age, depression, psychosis, medications, and NR3C1 genetic variation together significantly 
accounted for 44.4% of the variance, F(14,78)=4.45, p<.001. None of the other five genes 
(CRH, CRH-R1, CRH-R2, NR3C2, or FKBP5) significantly predicted evening cortisol (see 
supplemental material).
Similarly, only genetic variation in NR3C1 significantly predicted early morning cortisol 
from 1am to 9am. Age accounted for 15.0% of the variance (F(1,91)=16.00, p<.001. 
Together depression and psychosis accounted for an additional 0.6% of the variance, but did 
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not reach significance (change r2 = F(2,89)=.297, p=.74). The use of daily psychiatric 
medications accounted for an additional 4.3% of the variance (change r2 = F(1,88)=4.77, p=.
032). Genetic variation in NR3C1 considering all SNPs accounted for an additional 17.1% 
of the variance (change r2 = F(10,78)=2.38, p=.019). Four of the 9 individual NR3C1 SNPs 
in this gene attained significance individually (rs2918419, p=.017; rs10052957, p=.001; 
rs10482633, p=.017; and rs12655166, p=.048). Three of the SNPs, rs2918419, rs10052957, 
and rs10482633, predicted both evening and early morning cortisol. As indicated in Figure 
2, the significant SNPs are generally in low LD with one another, other than an r2 of 0.50 
observed between rs10052957 and rs10482633. Together, age, depression and psychosis 
severity, psychiatric medication use, and NR3C1 account for 37.0% of the variance 
(F(13,79)=3.56, p<.001). None of the other five genes (CRH, CRH-R1, CRH-R2, NR3C2, 
or FKBP5) significantly predicted early morning cortisol (see supplemental material).
Contributions of NR3C1 for each time point between 6 pm to 9 am were then calculated. As 
indicated in Figure 1b, significant contributions were observed from 6 pm to 1 am and at 8 
and 9 am but not from 1 to 7 am. This is consistent with cortisol loadings to NR3C1 
primarily at high cortisol concentrations (i.e., low affinity). The mean coefficient of 
variation (SD / Mean) for hourly cortisol levels was .687, with a range of .435 - .984, 
indicating that the distribution of significant genetic contribution to cortisol was not just due 
to lower variance around the nadir.
We then performed linear regression to predict depression severity with all subjects 
combined. Only one gene, CRHR1, predicted depression. At the first step, psychosis alone 
accounted for 28.4% of the variance, F(1,88)=34.8, p<.001. Once psychosis was accounted 
for, the CRHR1 gene accounted for an additional 24.2% of the variance, (F(20,68)=1.73, p=.
049. Together psychosis and CRHR1 accounted for 52.5% of the variance F(21, 68)=3.59, 
p<.001). Only one SNP attained significance-- rs4076452 (p=.019) and two were of trend 
significance—rs4792825, p=.079 and rs17763658, p=.089. No other gene (CRH, CRHR2, 
NR3C1, NR3C2, or FKBP5) was significant nor trended to predict depression severity (see 
supplemental material).
Of the 6 genes examined, both NR3C1 and CRHR1 significantly predicted psychosis 
severity once depression had been accounted for. After accounting for depression severity, 
the NR3C1 (GR) gene predicted 12.7% of the variance, F(9,82)=2.35, p=.044. Two SNPs in 
this gene trended toward individual significance for an association with psychosis—rs6198, 
p=.093 and rs12521436, p=.056. After accounting for depression severity, CRHR1 gene also 
predicted psychosis, F(20,68)=2.07, p=.014, accounting for 27.1% of the variance. Three 
SNPs in this gene attained individual statistical significance, rs110402, p=.023; rs4076452, 
p=.010; rs17763658, p=.040 and three trended toward significance: rs4792887, p=.10; 
rs4792888, p=.072; and rs4792825, p=.087. The other four genes (CRH, CRHR2, NR3C2, 
and FKBP5) did not predict psychosis (see supplemental material).
For all analyses, results were similar for the full sample (N=95) and for the subsample with 
European Caucasians only (N=69). In the Caucasian sample, the overall prediction of 
evening cortisol by NR3C1, with age, depression, psychosis, and daily psychiatric 
medications accounted for, held strong (change r2 = 37.5, p<.001) as did the results for 
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morning cortisol (change r2=26.2, p=.003). Regression results predicting psychosis once 
depression was accounted for were also similar. For psychosis, results accounted for similar 
amount of variance but were no longer significant. NR3C1 accounted for 16.5% of the 
variance, p=.083 and CRHR1 accounted for 27.0% of the variance, p=.26. For depression, 
results accounted for similar amounts of variance but were no longer trending towards 
significance: CRHR1 accounted for 23.5% of the variance, p=.42.
We followed our positive findings for NR3C1 with additional haplotype analyses of 
previously reported GR haplotypes (25, 26). No haplotype was significantly associated, with 
cortisol, psychosis or depression (see Supplemental materials).
Discussion
The data presented indicate that variation in NR3C1 (GR) gene is associated with elevations 
in cortisol levels (accounting for 29% of cortisol variance) and with psychosis in depression. 
NR3C1 mediated feedback has long been thought to play a potential role in the 
hypercortisolemia of major depression and was in part the basis of the application of the 
DST to assessing major depression with melancholia. However, two meta-analyses have 
indicated that the most significant contributor to DEX non-suppression in depression is the 
presence of psychosis (3, 8). Our data indicate that NR3C1 genetic variation contributes 
significantly to both psychosis in depression and to hypercortisolemia per se and suggest 
elevated cortisol levels may reflect deficits in feedback. However, DST’s were not 
performed in this study and thus we cannot be certain that these particular variants do 
account for poorer GC feedback.
A number of specific NR3C1 SNPs contributed significantly to hypercortisolemia after 
accounting for the effects of other SNPs, age, depression and psychosis severity and 
medication. (48, 49). Importantly, our data suggest that although medication effects 
contribute significantly for about 5% of the variance of cortisol levels, the majority of the 
variance (29%) is due to NR3C1 genetic variation. The Bcl1 (rs41423247) variant in 
NR3C1 appeared to contribute to nocturnal cortisol. This intronic SNP has no known effect 
on receptor function but has been reported to be associated with: poor negative feedback 
(50); elevated hormone responses to stress (51) increased risk for depression in 
premenopausal women (30); hypersensitivity to glucocorticoids and risk for depression (31); 
decreased activation of the prefrontal cortex on functional magnetic resonance imaging (f-
MRI) in healthy controls (28); as well as decreased NR3C1 transcription in the dorsolateral 
prefrontal cortex in patients with schizophrenia or bipolar disorder (52). It is likely in LD 
with a functional NR3C1 polymorphism. In the postmortem study, a dose dependent effect 
of the C allele was observed with C/C homozygotes demonstrating the lowest levels of 
expression. In our sample, we also observed a dose effect of the C allele on cortisol levels 
from 6pam-1am across all three groups after age was accounted for. It predicted 7.2% of the 
variance --F(1,92)=7.58, p=.007. PMD patients demonstrate poorer performance on 
prefrontal mediated—as well as other--tasks (13, 53), and most recently, we reported that 
prefrontal activation on f-MRI is significantly decreased in PMD in response to working and 
verbal memory tasks. These data point to a potential role for this SNP in the development of 
hypercortisolemia and its cognitive sequelae. Of the other contributing NR3C1 SNP’s, 
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rs33388 has been associated with poorer responses to lithium in bipolar disorder (54) and 
rs2918419 with insulin resistance in men- a possible sequelae of elevated cortisol levels 
(55). Both rs33388 and rs2918419 are intronic, and their effects are likely due to LD with 
one or more functional polymorphisms in NR3C1. Interestingly, rs41423247, rs33388, and 
rs2918419 are not in strong LD, suggesting that there may be more than one important as yet 
unknown functional variant that account for clinical prediction.
Regarding psychosis, the NR3C1 SNP rs6198 trended toward significance. This SNP is 
located in the 3′ UTR of exon 9β, and hence could affect mRNA stability or have other 
regulatory functions. Although rs6198 was not a significant predictor of hypercortisolemia, 
it is in moderate LD with the intronic SNP rs10482633 (r2 = 0.79), which was a predictor of 
cortisol levels. The rs6198 SNP is associated with alteration in mRNA stability of the GR-
beta isoform (50) and decreased GR sensitivity (26). It has also recently been associated 
with attention deficit disorder (29). Attentional deficits have been reported by our group in 
PMD cohort (53). In addition, the SNP may play a role in smoking behavior (56).
Our results also indicate that variation in the CRHR1 gene confers risk for both depression 
and psychosis, accounting for over 24% of each. CRH has effects via CRHR1 on both the 
HPA axis as well as on extra-hypothalamic CRHR1, particularly in the amygdala where it 
appears not to be under feedback inhibition control and mediates the cognitive and 
behavioral responses to stress (57). The possible effects in the amygdala may explain the 
lack of relationship of CRH in this study to cortisol levels. Of interest is that we have 
reported that PMD patients demonstrate smaller amygdalae in comparison to NPMD’s and 
HC’s.
Of the 3 SNP’s that were significant contributors to psychosis, rs110402 has been perhaps 
studied best. A few years ago, Ressler’s group reported an interaction of the SNP with early 
abuse in increasing risk for developing later depression (17). More recent reports indicate it 
appears to increase risk for major depression (58) and alcoholism or alcohol use disorder. 
Ray et al (59) reported an interaction of this allele with early trauma on increasing risk for 
alcoholism; however, the increased risk for alcohol abuse disorder may be independent of 
early abuse (60) and this SNP interact with another (rs3811939) to increase risk. 
Functionally, the SNP is associated with altered f-MRI responses to emotional stimuli in the 
amygdala, nucleus accumbens and hypothalamus on f-MRI (61) and increased cortisol 
responses to a Trier Social Stress Test (62). Of the SNP’s that were of trend significance, 
rs4792887 has been associated with the development of suicidal ideation in the face of mild 
stress and has also been thought to represent a locus for a gene-environment interaction (63).
We also determined the contribution of CRHR1 SNPs to depression alone by excluding 
those subjects with a history of psychosis. Genetic variation in CRHR1 overall separated 
NPMD from HC’s, χ2(20)=36.35, p=.011, R-square=67.4, correct classification=83.0%. 
Early child abuse has been associated with increased risk for major psychiatric syndromes in 
adulthood with part of the risk being attributed to CRHR1 SNPs. We are currently assessing 
our data to determine if we can address this possible contributing factor.
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One possible model to explain the relationship of CRH and GR to psychotic depression is to 
view patients with severe depression (both PMD and NPMD) as demonstrating a different 
pattern of CRH genetic variation than do HC’s with those depressed patients who develop 
psychosis and hypercortisolemia also demonstrating alterations in the GR gene. This would 
argue that PMD reflects alterations in two key components of the HPA axis. Still, the 
proportion of variance in cortisol levels or psychosis unaccounted for by NR3C1 and 
CRHR1 suggests that cortisol or NR3C1 or CRH genetic markers alone do not account for 
the entire risk for PMD. We have hypothesized that the effects of glucocorticoids on other 
systems—e.g., dopamine-- play a role in the pathophysiology of PMD and as such genetic 
alterations in these other systems may also confer risk for PMD. We are currently pursuing 
this hypothesis in other studies in our laboratory.
We did not assess genes for the CRHBP, AVP, or urocortin. These could play a role in 
cortisol or clinical symptoms but were beyond the scope of this study. There are a number of 
other limitations to this study, particularly the limited sample size and the number of SNPs 
assessed, and the lack of DST or another glucocorticoid challenge. The limited sample size 
is especially relevant for genes with a large numbers of SNPs. Consequently, we made a 
decision to conduct an overall analysis for each gene, rather than separate analyses for each 
SNP. While individual SNP results from models with all SNPs in the gene may be 
underpowered, an approach conducting single-SNP analyses without a prior gene-based test 
could be biased. Further studies on larger samples are required to replicate these findings 
and to better understand which specific variants account for severe depression.
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Figure 1. 
a. Mean Cortisol values across all subjects from 6 pm to 9 am.
b. Amount of cortisol variance accounted for by GR gene at each time point.
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Figure 2. 
Linkage disequilibrium (LD) map of the glucocorticoid receptor (NR3C1) locus showing 
pairwise r2 values between single nucleotide polymorphisms genotyped in this study. This 
shows that with the exception of rs6198 and rs10482633 which trend towards the .80 
threshold for strong LD the tested SNPs are independent in this population.
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Table 1
HPA axis Genes Assessed
Gene Function Brain Location in humans SNPs Studied
CRH Stimulates HPA axis; mediates
stress responses in amygdala
See below for CRH--R1
and CRH-R2
N=6
**rs10098823
rs3176921
^rs5030875
rs5030877
rs6999100
^rs7350113
CRHR1 Mediates stress responses and
HPA axis stimulation. Binds
primarily to CRH.
Distributed widely
throughout brain with
particular concentration in
the amygdala,
paraventricular nucleus of
the hypothalamus cortex –
prefrontal, cingulate,
striate, and insular. Also
located in locus coeruleus,
cerebellar cortex, solitary
tract nucleus, thalamus,
and striatum.
N=21
rs110402
*rs12938031
rs16940674
rs171440
rs17689966
rs242924
rs242940
rs242948
**rs4076452
**rs4792887
**rs4792888
rs7209436
^rs3785877
^rs4792825
rs4458044
rs12944712
**rs17763104
**rs2664008
**rs17763658
**rs242942
**rs11657992
CRHR2 Involved in appetitive behaviors
and stress; binds to both CRH and
urocortin
The distribution of CRH R-
2 in nonhuman primate is
similar to CRH-R1 and
includes cortex, amygdala,
and hippocampus. Also
reported in choroid plexus
nucleus prepostus, and
hypothalamus (supraoptic
and paraventicular nuclei).
Limited distribution in rat
brain.
N=18
**rs2240403
rs2267712
rs2267715
rs2267717_coded
rs2270007
rs255100
**rs4723003
**rs7812133
rs255102
rs975537
rs2190242
rs2267716
**rs2284216
rs2284217
**rs4723000
**rs12701020
**rs17159371
rs929377
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Gene Function Brain Location in humans SNPs Studied
NR3C1
(GR)
Feedback inhibition of HPA axis;
cognition; immune response
Cortex widely,
hypothalamus, amygdala,
hippocampus
N=10
*rs6195
**rs6198
rs33388
^rs2918419
rs10052957
 rs10482633
**rs12521436
**rs12655166
**rs17209258
rs41423247
NR3C2
(MR)
Inhibitory control of HPA axis;
memory; blood pressure
Hypothalamus,
hippocampus, amygdala
N=13
**rs5525
*rs5530
rs1879829
rs2070951
**rs2272089
rs3910052
rs4835488
rs6535578
rs7658048
**rs7694064
**rs10213471
*rs17024360
**rs17484245
rs2070950
**rs5522
FKBP5 Co-chaperone to heat shock
protein for GR; stabilizes GR
confirmation
See GR N=2
rs1360780
rs3800373
*
Little or no variance in the SNPs; SNP not used in analyses
**
Less than 5 total in the rare homozygous, collapsed into the heterozygous SNP group
^Only 2 SNP variations present
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Table 3
Demographic and Clinical Measures in Subjects
PMD
(N= 40)
NPMD
(N=26 )
HC
(N=29 )
Test Value Post-hoc
comparison
Age 39.33
(14.0)
40.81
(12.9)
35.41
(14.2)
F(2,92)=1.16, ns
Gender χ2(2)= 850, ns
 Female 20 16 16
 Male 20 10 13
Ethnicity^ X2(6)=6.25, ns
 Caucasian 30 20 19
 African-American 3 2 2
 Asian 5 2 8
 Latino 2 2 0
Any Daily
Psychiatric
Medication Use*
36/40 12/26 0/29
Education 15.10(2.9) 15.35
(1.9)
15.64
(2.1)
F(2,92)=418, ns
HDRS Total 28.90
(5.03)
23.73
(3.3)
.69 (1.0) F(2,92)=508.4,
p<.001
PMD > NPMD
> HC
HDRS
Endogenormophic
Subscale
9.1 (2.1) 8.15
(17)
.14 (.35) F(2,92)=275.6,
p<.001
PMD > NPMD
> HC
BPRS Total* 45.10(7.2)
33.38
(4.5)
18.79
(1.4)
F(2, 92)=207.1,
p<.001
PMD > NPMD
> HC
BPRS PSS* 10.08(4.1)
4.23
(.58)
4.10 (.41) F(2, 92)=54.75,
p<.001
PMD > (NPMD
= HC)
Cortisol 6pm – 1
am
4.93 (2.7) 3.65
(1.7)
3.65 (1.5) F(2,92)=4.19,
p=.018
PMD > (NPMD
= HC)
Cortisol 1 am – 9
am
9.73 (4.7) 8.68
(2.6)
8.93 (2.2) F(2,92)=.800, ns
Haplotype Carriers
 Hap 1 33/38 20/26 23/29
 Hap 2 16/38 15/26 14/29
 Hap 3 7/38 10/26 10/29
 Hap 4 10/38 6/26 7/29
 Hap5 1/38 0/26 1/29
 Hap 6 2/38 2/26 0/29
^
Ethnicity was assessed because SNP prevalence may differ between ethnic groups.
*Any daily psychiatric medication includes use of antidepressants, antipsychotics, anxiolytics, or mood stabilizers
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